China SXT Pharmaceuticals Management
Management criteria checks 3/4
China SXT Pharmaceuticals' CEO is Albert Zhou, appointed in Jan 2025, has a tenure of less than a year. total yearly compensation is $50.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $1.61K. The average tenure of the management team and the board of directors is 0.1 years and 3.8 years respectively.
Key information
Albert Zhou
Chief executive officer
US$50.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | less than a year |
| CEO ownership | 0.1% |
| Management average tenure | less than a year |
| Board average tenure | 3.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | US$50k | US$50k | -US$3m |
| Dec 31 2023 | n/a | n/a | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | US$50k | US$50k | -US$6m |
| Dec 31 2022 | n/a | n/a | -US$5m |
| Sep 30 2022 | n/a | n/a | -US$4m |
| Jun 30 2022 | n/a | n/a | -US$5m |
| Mar 31 2022 | US$50k | US$50k | -US$6m |
| Dec 31 2021 | n/a | n/a | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | US$50k | US$50k | -US$3m |
| Dec 31 2020 | n/a | n/a | -US$5m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | US$50k | US$50k | -US$10m |
| Dec 31 2019 | n/a | n/a | -US$6m |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | -US$132k |
| Mar 31 2019 | US$18k | US$18k | US$2m |
| Dec 31 2018 | n/a | n/a | US$1m |
| Sep 30 2018 | n/a | n/a | US$1m |
| Jun 30 2018 | n/a | n/a | US$1m |
| Mar 31 2018 | US$7k | US$7k | US$1m |
Compensation vs Market: Albert's total compensation ($USD50.00K) is below average for companies of similar size in the US market ($USD638.32K).
Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.
CEO
Albert Zhou (32 yo)
less than a year
Tenure
US$50,000
Compensation
Mr. Feng Zhou, also known as Albert, had been Interim Chief Financial Officer of China SXT Pharmaceuticals, Inc. since July 8, 2020 until February 1, 2021. Mr. Zhou had been Chief Executive Officer and ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & Co-CEO | less than a year | US$50.00k | 0.12% $ 1.6k | |
| Chief Financial Officer | 3.1yrs | US$50.00k | no data | |
| Executive Director | no data | no data | no data | |
| Co-Chief Executive Officer | less than a year | no data | no data |
0.08yrs
Average Tenure
46yo
Average Age
Experienced Management: SXTC's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & Co-CEO | 7.6yrs | US$50.00k | 0.12% $ 1.6k | |
| Executive Director | 6.1yrs | no data | no data | |
| Independent Director | 3.8yrs | no data | no data | |
| Independent Director | 2.8yrs | no data | no data | |
| Independent Director | less than a year | no data | no data |
3.8yrs
Average Tenure
45.5yo
Average Age
Experienced Board: SXTC's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/17 12:58 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China SXT Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.